Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome

NCT01903460 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Alagille Syndrome

Interventions

DRUG: LUM001
DRUG: Placebo

Sponsor

Mirum Pharmaceuticals, Inc.